Lavipharm S.A (LAVI) - Cash Flow Conversion Efficiency

Latest as of December 2022: 0.013x

Based on the latest financial reports, Lavipharm S.A (LAVI) has a cash flow conversion efficiency ratio of 0.013x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€527.00K ≈ $616.12K USD) by net assets (€40.28 Million ≈ $47.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Lavipharm S.A - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Lavipharm S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Lavipharm S.A total liabilities for a breakdown of total debt and financial obligations.

Lavipharm S.A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lavipharm S.A ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Tudor Gold Corp V:TUD	-0.003x
Yongyue Science & Tech Co Ltd SHG:603879	-0.044x
Lionheart Holdings Unit NASDAQ:CUBWU	-0.001x
HCM IV Acquisition Corp. Class A Ordinary Share NASDAQ:HACQ	N/A
TYC Brother Industrial Co Ltd TW:1522	0.020x
Valuetronics Holdings Limited F:GJ7	0.021x
Incap Oyj HE:ICP1V	0.046x
CompX International Inc NYSE MKT:CIX	0.087x

Annual Cash Flow Conversion Efficiency for Lavipharm S.A (2014–2024)

The table below shows the annual cash flow conversion efficiency of Lavipharm S.A from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Lavipharm S.A.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€52.97 Million ≈ $61.92 Million	€4.64 Million ≈ $5.42 Million	0.088x	+1219.29%
2023-12-31	€42.77 Million ≈ $50.00 Million	€284.00K ≈ $332.03K	0.007x	-92.01%
2022-12-31	€40.28 Million ≈ $47.09 Million	€3.35 Million ≈ $3.91 Million	0.083x	+121.62%
2021-12-31	€-9.94 Million ≈ $-11.62 Million	€3.82 Million ≈ $4.46 Million	-0.384x	-65.91%
2020-12-31	€-12.30 Million ≈ $-14.38 Million	€2.85 Million ≈ $3.33 Million	-0.232x	-15.32%
2019-12-31	€-14.40 Million ≈ $-16.84 Million	€2.89 Million ≈ $3.38 Million	-0.201x	-176.84%
2018-12-31	€-19.53 Million ≈ $-22.83 Million	€1.42 Million ≈ $1.66 Million	-0.073x	+4.54%
2017-12-31	€-19.92 Million ≈ $-23.29 Million	€1.51 Million ≈ $1.77 Million	-0.076x	-299.17%
2016-12-31	€-31.82 Million ≈ $-37.21 Million	€606.00K ≈ $708.48K	-0.019x	-112.96%
2015-12-31	€-64.42 Million ≈ $-75.31 Million	€576.00K ≈ $673.40K	-0.009x	+81.60%
2014-12-31	€-48.96 Million ≈ $-57.24 Million	€2.38 Million ≈ $2.78 Million	-0.049x	--

About Lavipharm S.A

AT:LAVI Greece Drug Manufacturers - Specialty & Generic

Market Cap

$327.67 Million

€280.27 Million EUR

Market Cap Rank

#15267 Global

#40 in Greece

Share Price

€1.66

Change (1 day)

+6.69%

52-Week Range

€0.74 - €1.70

All Time High

€2.05